Omeros (STU:3O8) Cyclically Adjusted Book per Share: €-1.62 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3O8 Omeros Corp STU:3O8
33 GF Score
Price €16.50
! 6 Warning Signs
View Full Analysis

What is Omeros Cyclically Adjusted Book per Share?

Omeros STU:3O8 +3.13% 33 Cyclically Adjusted Book per Share is €-1.62 as of Jun. 2026. GuruFocus rates STU:3O8 with a GF Score™ of 33/100. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Omeros's adjusted book value per share for the three months ended in Jun. 2026 was €-0.618. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €-1.62 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -10.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Omeros was -4.10% per year. The lowest was -35.50% per year. And the median was -11.80% per year.

As of today (2026-08-22), Omeros's current stock price is €16.50. Omeros's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €-1.62. Omeros's Cyclically Adjusted PB Ratio of today is .


Omeros  (STU:3O8) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Omeros Cyclically Adjusted Book per Share Related Terms


Omeros Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Omeros's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omeros Cyclically Adjusted Book per Share Chart

Omeros Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.21 -1.21 -1.25 -1.69 -1.45

Omeros Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.51 -1.55 -1.45 -1.61 -1.62

STU:3O8 vs STTK, BBOT, XOMA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Omeros's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omeros Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Omeros's Cyclically Adjusted PB Ratio falls into.


STU:3O8
33GF Score
Omeros Corp STU:3O8
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Omeros Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Omeros's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.618/333.9520*333.9520
=-0.618

Current CPI (Jun. 2026) = 333.9520.

Omeros Quarterly Data

Book Value per Share CPI Adj_Book
201609 -0.473 241.428 -0.654
201612 -0.810 241.432 -1.120
201703 -1.024 243.801 -1.403
201706 -1.098 244.955 -1.497
201709 0.161 246.819 0.218
201712 -0.049 246.524 -0.066
201803 -0.491 249.554 -0.657
201806 -0.994 251.989 -1.317
201809 -1.556 252.439 -2.058
201812 -1.796 251.233 -2.387
201903 -2.185 254.202 -2.870
201906 -2.344 256.143 -3.056
201909 -2.565 256.759 -3.336
201912 -1.810 256.974 -2.352
202003 -2.189 258.115 -2.832
202006 -2.627 257.797 -3.403
202009 -1.203 260.280 -1.544
202012 -1.609 260.474 -2.063
202103 -2.995 264.877 -3.776
202106 -3.271 271.696 -4.021
202109 -3.570 274.310 -4.346
202112 0.336 278.802 0.402
202203 -0.071 287.504 -0.082
202206 -0.493 296.311 -0.556
202209 -0.746 296.808 -0.839
202212 1.287 296.797 1.448
202303 0.817 301.836 0.904
202306 0.301 305.109 0.329
202309 -0.208 307.789 -0.226
202312 -0.375 306.746 -0.408
202403 -1.133 312.332 -1.211
202406 -1.998 314.175 -2.124
202409 -2.397 315.301 -2.539
202412 -3.004 315.605 -3.179
202503 -3.402 319.799 -3.553
202506 -3.303 322.561 -3.420
202509 -2.681 324.800 -2.757
202512 -1.445 324.054 -1.489
202603 -0.761 330.213 -0.770
202606 -0.618 333.952 -0.618

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €-1.62 mean?
Omeros (STU:3O8) has a Cyclically Adjusted Book per Share of €-1.62 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Omeros and its competitors.
Is Omeros' Cyclically Adjusted Book per Share too high?
Omeros' current Cyclically Adjusted Book per Share is €-1.62. Overall, Omeros has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Omeros' Cyclically Adjusted Book per Share compare to STTK and BBOT?
Omeros' Cyclically Adjusted Book per Share of €-1.62 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Omeros and its competitors. Omeros's current Cyclically Adjusted Book per Share is €-1.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omeros stock overvalued right now?
Omeros (STU:3O8) has a current Cyclically Adjusted Book per Share of €-1.62. The current Cyclically Adjusted Book per Share is €-1.62. Omeros' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Omeros (STU:3O8), the current Cyclically Adjusted Book per Share is €-1.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Omeros Business Description

Other Exchanges OMER:USA0KBU:UK
Address 201 Elliott Avenue West, Seattle, WA, USA, 98119
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
33GF Score

Get the complete analysis for STU:3O8

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.50
Price